foxo4-dri human trial senolytic The costs and benefits of senotherapeutics for health Buy FOXO4-DRI | Exceptional 99%+
Buy FOXO4 DRI Exceptional 99%+ Purity Third Party COA Included Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Peptide Inhibitors Targeting FOXO4 p53 Interactions and Inducing Senescent Cancer Cell specific Apoptosis Journal of Medicinal Chemistry
Pay in 4 interest-free payments of $6.91 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15



